Good News | Shenzhen Cell Valley Secures Three Additional Invention Patents!

Recently, Shenzhen Cell Valley and its wholly-owned subsidiary, Guangdong Junhou Biopharmaceutical Co., Ltd., achieved another milestone in intellectual property, being granted three invention patents by the China National Intellectual Property Administration (CNIPA).

01. Packaging Method for BaEV Retroviral Vectors and Their Packaging Cell Lines

Applied for on August 17, 2024, this patent underwent nearly a year of rigorous examination and uation before being officially granted by the CNIPA on June 13, 2025. This innovative breakthrough provides a novel technical pathway for the efficient packaging of retroviral vectors. It is poised to play a pivotal role in the field of gene therapy, offering safer and more effective vector tools for the treatment of various diseases.

02. Preparation Method for PSR.Syn.CD19.CD38 CAR-T Cells, Along with the Cells and Their Applications

03. Preparation Method for Syn-CAR-T Cells, Along with the Cells and Their Applications

Both patents were filed on November 15, 2024, and, following a similarly strict review process spanning nearly a year, were officially authorized by the CNIPA on June 13, 2025.

The innovative preparation methods for PSR.Syn.CD19.CD38 CAR-T cells and Syn-CAR-T cells represent significant technological advancements in the realm of CAR-T cell therapy. By optimizing the design and manufacturing processes of CAR-T cells, these innovations aim to enhance cell specificity, targeting capabilities, and persistence in vivo. This opens new avenues for the precision treatment of malignant diseases, particularly hematological tumors.

The granting of these three invention patents marks another critical breakthrough in technological innovation for Shenzhen Cell Valley and Guangdong Junhou. Looking ahead, the Cell Valley Group’s R&D and production headquarters will continue to increase investment in research, deepen industry-academia-research collaborations, and focus on the exploration and application of cutting-edge technologies to fuel the high-quality development of the biopharmaceutical industry.

Furthermore, we will strengthen intellectual property protection to facilitate the efficient translation and application of our innovative achievements. Working in synergy with the Group’s International Business Department, we aim to accelerate our global expansion strategy, delivering superior and advanced medical solutions to patients worldwide.